SAN

96.15

-3.49%↓

EI

244.1

-1.89%↓

SHL.DE

44.49

-4.08%↓

ARGX

520.2

-2.91%↓

FRE

38.02

-4.35%↓

SAN

96.15

-3.49%↓

EI

244.1

-1.89%↓

SHL.DE

44.49

-4.08%↓

ARGX

520.2

-2.91%↓

FRE

38.02

-4.35%↓

SAN

96.15

-3.49%↓

EI

244.1

-1.89%↓

SHL.DE

44.49

-4.08%↓

ARGX

520.2

-2.91%↓

FRE

38.02

-4.35%↓

SAN

96.15

-3.49%↓

EI

244.1

-1.89%↓

SHL.DE

44.49

-4.08%↓

ARGX

520.2

-2.91%↓

FRE

38.02

-4.35%↓

SAN

96.15

-3.49%↓

EI

244.1

-1.89%↓

SHL.DE

44.49

-4.08%↓

ARGX

520.2

-2.91%↓

FRE

38.02

-4.35%↓

Search

Laboratorios Farmaceuticos Rovi SA

Fermé

SecteurSoins de santé

49.04 -4.22

Résumé

Variation du prix de l'action

24h

Actuel

Min

48.56

Max

49.24

Chiffres clés

By Trading Economics

Revenu

-57M

32M

Ventes

199M

434M

P/E

Moyenne du Secteur

19.288

63.778

BPA

0.457

Rendement du dividende

2.11

Marge bénéficiaire

7.411

Employés

2,197

EBITDA

40M

138M

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+58.54% upside

Dividendes

By Dow Jones

Rendement du dividende

Moyenne du Secteur

2.11%

2.39%

Prochains Résultats

7 mai 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-770M

2.6B

Ouverture précédente

53.26

Clôture précédente

49.04

Sentiment de l'Actualité

By Acuity

25%

75%

48 / 386 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Weak Bearish Evidence

Laboratorios Farmaceuticos Rovi SA Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

4 avr. 2025, 22:38 UTC

Actions en Tendance

Stocks to Watch: Eli Lilly, Novo Nordisk, Hims & Hers, Maxeon Solar Technologies

5 avr. 2025, 09:30 UTC

Résultats

Elon Musk's Mr. Fix-It Takes Center Stage During a Really Bad Week -- WSJ

5 avr. 2025, 01:00 UTC

Acquisitions, Fusions, Rachats

How BlackRock's Larry Fink Won Over Donald Trump -- WSJ

5 avr. 2025, 01:00 UTC

Acquisitions, Fusions, Rachats

How BlackRock's Larry Fink Won Over Donald Trump -- WSJ -2-

4 avr. 2025, 21:53 UTC

Market Talk

Maxeon's Supply Chain Move at Critical Time for Solar Panel Cos -- Market Talk

4 avr. 2025, 21:44 UTC

Actualités
Acquisitions, Fusions, Rachats

Trump Grants 75-Day Extension to Reach TikTok Deal -- 3rd Update

4 avr. 2025, 21:00 UTC

Actualités

Americans Were Souring on Trump's Economic Plans Even Before Tariff Bloodbath -- WSJ

4 avr. 2025, 20:52 UTC

Market Talk

Peloton Likely to Escape Tariffs Unscathed -- Market Talk

4 avr. 2025, 20:52 UTC

Actualités

Trump Can Cut Teacher-Training Programs For Now, Supreme Court Says -- WSJ

4 avr. 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

4 avr. 2025, 20:48 UTC

Actualités

The Score: Nike, Apple, Stellantis and More Stocks That Defined the Week -- WSJ

4 avr. 2025, 20:45 UTC

Actualités

Hiring Defied Expectations in March, With 228,000 New Jobs -- 6th Update

4 avr. 2025, 20:32 UTC

Actualités

Dow Tumbles 2,000 Points, Bonds Rally After China Retaliates Against Trump Tariffs -- WSJ

4 avr. 2025, 20:21 UTC

Actualités

China Hits Back at Trump With Sweeping Tariffs on All U.S. Goods -- Update

4 avr. 2025, 20:00 UTC

Actualités

Republicans March Ahead on Trump's Tax Cuts as Tariffs Kick In -- WSJ

4 avr. 2025, 19:51 UTC

Market Talk

Dollar Recovers While Recession Fears Grip Wall Street -- Market Talk

4 avr. 2025, 19:37 UTC

Actualités

Trump's Team is Getting the Bond Rally It Wanted. But for the Wrong Reasons. -- WSJ

4 avr. 2025, 19:32 UTC

Market Talk

Oil Selloff Continues as China Responds to U.S. Tariffs -- Market Talk

4 avr. 2025, 19:28 UTC

Actualités

U.S. Stocks Fall Further After China Retaliates Against Trump Tariffs -- Update

4 avr. 2025, 19:15 UTC

Market Talk

Costco Gold, Membership Fees Could Help Cushion from Tariff Costs -- Market Talk

4 avr. 2025, 19:12 UTC

Actualités

Powell Warns of Higher Prices, Weaker Growth After Tariff Plan -- 3rd Update

4 avr. 2025, 19:11 UTC

Market Talk

U.S. Natural Gas Falls as Global Selloff Continues -- Market Talk

4 avr. 2025, 19:09 UTC

Market Talk

Mexican Stocks, Peso Tumble as Global Rout Continues -- Market Talk

4 avr. 2025, 19:09 UTC

Actualités

Trump Grants 75-Day Extension to Reach TikTok Deal -- Second Update

4 avr. 2025, 19:00 UTC

Market Talk

Fed Has Limited Options to Counter Tariffs -- Market Talk

4 avr. 2025, 18:53 UTC

Market Talk

Brace for Trump's Tariff Order to Remain in Place for Extended Period -- Market Talk

4 avr. 2025, 18:51 UTC

Market Talk

Morgan Stanley Analysts Outline Paths to Recession -- Market Talk

4 avr. 2025, 18:44 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

4 avr. 2025, 18:44 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

4 avr. 2025, 18:44 UTC

Market Talk

Tariffs Won't Achieve What Trump Wants, Morgan Stanley Says -- Market Talk

Comparaison

Variation de prix

Laboratorios Farmaceuticos Rovi SA prévision

Objectif de Prix

By TipRanks

58.54% hausse

Prévisions sur 12 Mois

Moyen 77.75 EUR  58.54%

Haut 90 EUR

Bas 65.5 EUR

Basé sur 2 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

2 ratings

2

Achat

0

Maintien

0

Vente

Score Technique

By Trading Central

N/A / 52.25Support & Résistance

Court Terme

Weak Bearish Evidence

Moyen Terme

Neutral Evidence

Long Terme

Weak Bearish Evidence

Sentiment

By Acuity

48 / 386Classement par Soins de santé

Sentiment de l'Actualité

Très Fortes Indications Haussières

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Inférieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Laboratorios Farmaceuticos Rovi SA

Laboratorios Farmaceuticos Rovi, S.A. engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally. The company provides products for cardiology, osteoarticular/women's health, anesthesia /pain, diagnostic imaging contrast agents, central nervous system, urology, endocrinology, respiratory, and primary healthcare areas. Its principal products include Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Medicebran, Medikinet, Mysimba, Orvatez, Tryptizol, Ulunar Breezhaler, and Volutsa; and hospital products, such as Iomeron and Iopamiro, Multihance and Y Prohance, Sonovue, Empowercta+, Empowermr, and CT Express, Fibrilin, and Sodium Heparin Rovi. It also provides contract-manufacturing services to other companies for a range of pharmaceutical forms, including prefilled syringes, vials, suppositories, tablets, and sachets. Laboratorios Farmaceuticos Rovi, S.A. was incorporated in 1946 and is headquartered in Madrid, Spain. Laboratorios Farmaceúticos Rovi, S.A. is a subsidiary of Norbel Inversiones, S.L.